PALL CORPORATION
NYSE : PLL

PALL CORPORATION

October 31, 2005 16:13 ET

Pall Prion Removal Technology Presented to FDA Advisory Committee on Transmissible Spongiform Encephalopathies; Protecting the Blood Supply from Variant CJD

EAST HILLS, N.Y.--(CCNMatthews - Oct 31, 2005) -

At the request of the Food and Drug Administration (FDA) Transmissible Spongiform Encephalopathies (TSEs) Advisory Committee, Pall Corporation (NYSE: PLL) today presented the latest research results on its prion technology to remove TSE infectivity from blood. The Pall Leukotrap® Affinity Prion Reduction Filter system is the only Council of Europe (CE) marked technology shown to remove prions from red blood cells, the most commonly transfused blood component. Samuel Coker, PhD, Principal Scientist and Technical Director of Pall Medical, who has been spearheading the research effort, gave the Committee a first-hand look at the validation studies on the performance characteristics of the prion reduction technology filter that were used to earn its CE mark in Europe. He also presented new results on quality control measures for blood banks to use upon implementation of prion reduction as a means to prevent transfusion-transmitted variant Creutzfeldt-Jakob Disease (vCJD).

TSEs, also called prion diseases, are fatal neurodegenerative diseases that include vCJD, the human form of bovine spongiform encephalopathy (BSE), or "mad cow disease." The presentation, part of the Advisory Committee's discussion on labeling claims for TSE clearance studies for blood component filters, is a continuation of Pall Corporation's dialogue with U.S. regulatory and health authorities on protecting the blood supply from prions that can cause vCJD.

Studies Validating Filter Performance

Dr. Coker presented research results on the ability of the filter to remove all types of prions from red cells including scrapie (a TSE affecting sheep); mouse infected with human variant CJD (mvCJD) and human sporadic CJD (sCJD). Sporadic CJD is the most common form of CJD affecting people.

He provided results of bioassays to provide a quantitative method to determine log removal of infectious prion in hamsters. (Hamsters are recognized as an optimal animal model for studying prion diseases.) These studies found that the technology was effective in reducing infectious prions in the human sCJD, scrapie and mvCJD models.

"These results demonstrate robust performance of the Leukotrap Affinity Prion Reduction Filter in removing different strains of prions," said Dr. Coker.

Dr. Coker reviewed results of studies on the safety of the product and details on the measurement of the quality of red cells post prion reduction, including survival, maintaining their integrity and therapeutic value (oxygen carrying properties) and other metabolic activities. On all counts measured, the studies found that the safety of processed red cells was not impaired.

Implementing Prion Reduction into Routine Blood Banking Practice

He also presented results of a new study that identified a surrogate marker to measure prion removal in order to enable quality control in the blood banking process. A surrogate marker is required since concentrations of infectious prion in blood are too low to measure using currently available methods. After review of a number of potential markers, the studies validated that reduction of a plasma protein present in blood and blood components directly correlated with reduction of infectious prion.

Dr. Coker explained, "These findings provide a feasible means for quality control for blood banks in their prion reduction process since the plasma protein can easily be measured with currently available analytical methods."

Studies on the efficacy of the filter's removal of prions under different processing conditions, which can vary by blood center and country in their use of anticoagulants, red cell storage solutions, temperatures, etc., were also reviewed. The studies showed about 99.9 percent prion removal across all conditions.

"The data show that the Leukotrap® Affinity Prion Reduction Filter is consistently effective in removing different strains of prions over a broad range of processing conditions," added Dr. Coker.

The Pall Leukotrap® Affinity Prion Reduction Filter system is available in Europe, where the vast majority of vCJD cases have occurred, as a CE marked medical device. The National Blood Service in England and the Irish Blood Transfusion Service are currently evaluating the technology for integration into routine blood processing to help prevent transfusion transmission of infectious prions that can cause vCJD. The Pall prion reduction technology is designed to reduce leukocytes (white blood cells) and prions in a single step.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9 billion. The Company headquarters is in East Hills, New York, with extensive operations throughout the world. Visit Pall at www.pall.com.

Editor's Note: Photos and additional information can be found on http://www.pall.com/corporate_38562.asp

MULTIMEDIA AVAILABLE:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5008499



Contact Information